Biontech Se (BNTX)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
Observing the fourth quarter of 2022 effort, the Biotechnology & Pharmaceuticals company's had top-line remained unaltered
BNTX reported fourth quarter of 2022 operating shortfall of $0 million
Published Mar 28 2023
Goran Soko / CSIMarket.com Contributer
![pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg "pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
For the most recent fiscal period BNTX reached balanced books of $0.00 per share compare to $0.00 a year prior and from $0.00 per share from the preceding reporting season. The revenue remained unchanged to $0.00 million from $0.00 million in the comparable reporting season a year prior and sequentially from $0.00 million.
Net income of $10,566.528 million in the most recent fiscal period fell by -8.34 % from $11,527.600 million in the corresponding period a year before.
the Biotechnology & Pharmaceuticals company reported deficit of $10.57 billion and revenue of $0.00 million in the fiscal period 2022.
Biontech Se reported further balanced books in proportion to $0.00 in the preceding fiscal year, while by 0 % from $0.00 million a year prior.
Biontech Se is expected to report next financial results on March 26, 2024.